Dr Dirk Bredenbröker joins leading herbal medicine manufacturer

Dr. Dirk Bredenbröker

Neumarkt, 19 July 2017 - Dr Dirk Bredenbröker was appointed head of R&D at Bionorica at the beginning of July. He will oversee a team of more than 40 people and report directly to Professor Michael A. Popp, owner and CEO of Bionorica SE. "We are delighted to have gained the services of Dr Bredenbröker, an expert who brings 18 years of experience in the pharmaceutical industry, particularly in cross-border clinical research and various therapeutic areas," says Professor Popp. The goal was to work together to bring R&D at Bionorica to the next level. "Bionorica is the market leader in scientifically substantiated phytomedicine, a segment which is expanding worldwide. Our research activities, in which we invested around 14 percent of our revenue in 2016, have played a crucial role in this success." This R&D investment quota puts Bionorica among the forerunners in the German pharmaceutical industry1. The company has also established research allian ces with more than 500 leading institutes, hospitals and universities worldwide.

Dr Bredenbröker, who has headed the international R&D divisions at four pharmaceutical companies, is already looking forward to his new professional challenge: "Bionorica is an innovative company in the field of phytotherapy, and in particular, in respect of research into new active ingredients and herbal medicines. We use the latest methods to prove their effectiveness and safety. In keeping with Bionorica's 'phytoneering' philosophy, my team and I will be focusing on developing the connection between cutting-edge clinical research and the wealth of experience afforded by herbal medicine."

The 47-year-old consultant in clinical pharmacology completed his doctorate in pulmonary medicine at the Philipps University of Marburg in 1997. In his last position Dr Bredenbröker served for four years as Vice President of the Established Products and Global Medical Affairs Division at Takeda Pharmaceuticals International AG in Zurich. Previously, at the Japanese pharmaceutical company's European Development Center, his responsibilities had included clinical development in immunology and respiratory tracts. A native of Wolfsburg, Dr Bredenbröker resides in Constance and Neumarkt, has a 17-year-old daughter, and likes to spend time with his partner at Lake Constance. Dr Bredenbröker's predecessor, Dr Aldo Ammendola, has left Bionorica.

1) According to the German Association for the Pharmaceutical Industry (BPI), the R&D quota of the pharmaceutical industry in Germany was just above 12 percent in 2015. The 2016 data are due to be published in April 2018.


Bionorica SE
Kerschensteinerstraße 11-15
D-92318 Neumarkt, Germany
phone +49 9181/231-7289

e-mail: unternehmenskommunikation@bionorica.de